Inhibition of allogeneic inflammatory responses by the Ribonucleotide Reductase Inhibitors, Didox and Trimidox
<p>Abstract</p> <p>Background</p> <p>Graft-versus-host disease is the single most important obstacle facing successful allogeneic stem cell transplantation (SCT). Even with current immunosuppressive therapies, morbidity and mortality rates are high. Current therapies in...
Main Authors: | Inayat Mohammed S, El-Amouri Ismail S, Bani-Ahmad Mohammad, Elford Howard L, Gallicchio Vincent S, Oakley Oliver R |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2010-08-01
|
Series: | Journal of Inflammation |
Online Access: | http://www.journal-inflammation.com/content/7/1/43 |
Similar Items
-
The efficacy of the ribonucleotide reductase inhibitor Didox in preclinical models of AML.
by: Guerry J Cook, et al.
Published: (2014-01-01) -
Advances of Ribonucleotide Reductase Inhibitors on Cancer
by: WANG An'ge, et al.
Published: (2019-08-01) -
Inhibitors of the Cancer Target Ribonucleotide Reductase, Past and Present
by: Sarah E. Huff, et al.
Published: (2022-06-01) -
Convergent allostery in ribonucleotide reductase
by: William C. Thomas, et al.
Published: (2019-06-01) -
Structure-guided design of anti-cancer ribonucleotide reductase inhibitors
by: Tessianna A. Misko, et al.
Published: (2019-01-01)